Detecting Diabetic Neuropathy Early with the TM-Flow System
Diabetic neuropathy affects up to 50 percent of long-term diabetes patients and often begins with subtle nerve damage before overt symptoms appear. Small-fiber neuropathy—affecting pain and temperature fibers—is particularly difficult to detect with traditional methods. The TM-Flow System offers a non-invasive, objective way to measure these early autonomic and sensory changes, empowering clinicians to act before irreversible damage occurs.
As with any diagnostic device, neuropathy screening protocols should account for device contraindications and proper use — see the product safety information for the FDA-cleared TM-Flow System.
A thorough diabetic foot exam remains the front line for catching these complications before they progress.
Understanding Diabetic Neuropathy
Chronic hyperglycemia leads to oxidative stress, microvascular ischemia and metabolic damage to nerve fibers. Small fibers are often affected first, causing burning, tingling, or sweating abnormalities. By the time nerve-conduction studies show abnormality, significant damage has occurred. Early detection allows for glycemic optimization and neuroprotective interventions.
The Challenge of Early Diagnosis
Traditional tests like monofilament and tuning fork are subjective and detect only late stages. Nerve conduction studies evaluate large fibers and miss small-fiber neuropathy. This creates a diagnostic gap in diabetic care—precisely where the TM-Flow System adds value. It quantifies sudomotor function (sweat gland response), HRV, and vascular indices in a single, 10-minute procedure. (PrimaryCareDiagnostics.com)
TM-Flow System Overview for Diabetes Care
- Sudomotor Testing: The SweatC module measures skin conductance changes to assess autonomic small-fiber function. Low conductance indicates neuropathy.
- HRV Analysis: Assesses autonomic balance—reduced HRV signals autonomic dysfunction common in diabetes. (TMFlowSystem.com)
- ABI Measurement: Screens for PAD, a common complication in diabetes, with automated accuracy.
- Together, these parameters offer a multi-system snapshot of neurological and vascular health.
Integrating TM-Flow in Diabetes Clinics
Endocrinologists can include the TM-Flow test in annual neuropathy screening or as part of the comprehensive metabolic assessment. Workflow: patient registration → vitals → TM-Flow test → results → physician discussion. Each session takes 7–12 minutes and is handled by trained assistants.
Case Example
A 58-year-old male with type 2 diabetes for 8 years complained of mild foot numbness. Routine exam was normal. TM-Flow revealed abnormal sudomotor conductance and low HRV, confirming autonomic neuropathy. Lifestyle intervention and tight glycemic control were initiated early, preventing ulcer progression.
Benefits for Clinicians and Patients
- Quantifies early neuropathy objectively
- Improves coding and documentation for reimbursement
- Engages patients in preventive care
- Enhances outcomes and reduces amputation risk
FAQs
- Is the test pain-free? Yes, completely non-invasive.
- Can I use it for type 1 and type 2 diabetes? Yes.
- How often should patients be tested? Annually for stable, semi-annually for high risk.
- Does insurance cover it? Yes, under neuropathy and autonomic testing codes.
- Can it detect prediabetic neuropathy? Emerging data suggests yes.
- Does it replace NCS? No, it complements it.
Conclusion
For diabetes clinics, the TM-Flow System bridges a critical gap in early neuropathy detection, offering objective, quantifiable data to guide proactive care and reduce complications.
Ready to get started? Learn how HealthWright Advantage bundles the device, training, and ongoing support your practice needs — backed by a 90-day buyback guarantee.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis, treatment, and clinical decision-making.
Frequently Asked Questions
How does the TM-Flow System support early diabetic neuropathy detection?
The TM-Flow System measures sudomotor (sweat-gland) function and heart-rate variability, which can reflect small-fiber and autonomic nerve changes that sometimes appear before overt symptoms. These are objective measurements used to support a physician’s clinical assessment, not a stand-alone diagnosis.
Is the testing invasive or painful for diabetic patients?
No. The measurements are non-invasive and are typically completed in a single short office visit.
Which CPT codes are associated with the measurements?
The measurements correspond to established codes such as sudomotor function (CPT 95923) and heart-rate variability (CPT 95921). Code selection, documentation, and coverage are the responsibility of the billing provider and should be verified against current payer policy.
Does the TM-Flow System replace nerve conduction studies?
No. It complements other evaluations. The CMAT Advantage System provides autonomic and small-fiber measurements that can prompt earlier follow-up, while nerve conduction studies assess large-fiber function.
CPT codes are provided for informational purposes only and do not guarantee reimbursement. Verify code applicability and coverage with the relevant payer and your billing department before submitting claims. CPT® is a registered trademark of the American Medical Association.
Ready to see the CMAT Advantage in your practice?
Book a free 15-minute demo — see the full PAD + autonomic workup and triple-CPT billing potential, with no obligation. Backed by our 90-day buyback guarantee.
Book a Free Demo →
